NCT02389985: A trial that was reported late by NewLink Genetics Corporation
This trial has reported, although it was 662 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02389985 |
|---|---|
| Title | A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 31, 2015 |
| Completion date | June 4, 2018 |
| Required reporting date | June 4, 2021, midnight |
| Actual reporting date | March 28, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 662 |